EP Patent

EP2638042A1 — Piperidinone carboxamide azaindane cgrp receptor antagonists

Assigned to Organon Pharma UK Ltd · Expires 2013-09-18 · 13y expired

What this patent protects

The present invention is directed to piperidinone carboxamide azaindane derivatives of formula I which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharma…

USPTO Abstract

The present invention is directed to piperidinone carboxamide azaindane derivatives of formula I which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Drugs covered by this patent

Patent Metadata

Patent number
EP2638042A1
Jurisdiction
EP
Classification
—
Expires
2013-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Organon Pharma UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.